Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
- DOI
- 10.1186/s13223-022-00721-y
- Published
- 2022-09-24
- Container
- Allergy, Asthma & Clinical Immunology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s13223-022-00721-y,
title = {Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies},
author = {Timothy J. Craig and Rafael H. Zaragoza-Urdaz and H. Henry Li and Ming Yu and Hong Ren and Salomé Juethner and John Anderson and Unknown},
year = {2022},
journal = {Allergy, Asthma \& Clinical Immunology},
doi = {10.1186/s13223-022-00721-y},
url = {https://doi.org/10.1186/s13223-022-00721-y}
}RIS
TY - JOUR TI - Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies AU - Timothy J. Craig AU - Rafael H. Zaragoza-Urdaz AU - H. Henry Li AU - Ming Yu AU - Hong Ren AU - Salomé Juethner AU - John Anderson AU - Unknown PY - 2022 JO - Allergy, Asthma & Clinical Immunology DO - 10.1186/s13223-022-00721-y UR - https://doi.org/10.1186/s13223-022-00721-y ER -
APA
Craig, T. J., Zaragoza-Urdaz, R. H., Li, H. H., Yu, M., Ren, H., Juethner, S., Anderson, J., & Unknown (2022). Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies. Allergy, Asthma & Clinical Immunology. https://doi.org/10.1186/s13223-022-00721-y
Source records
- crossref · retrieved 2026-09-26T21:25:17.597Z